Lithium induces microcysts and polyuria in adolescent rat kidney independent of cyclooxygenase-2
Authors:
Open Access
- 22 January 2014
- journal article
- research article
- Published by Wiley in Physiological Reports
- Vol. 2 (1) , e00202
Abstract
In patients, chronic treatment with lithium leads to renal microcysts and nephrogenic diabetes insipidus (NDI). It was hypothesized that renal cyclooxygenase‐2 (COX‐2) activity promotes microcyst formation and NDI. Kidney microcysts were induced in male adolescent rats by feeding dams with lithium (50 mmol/kg chow) from postnatal days 7–34. Lithium treatment induced somatic growth retardation, renal microcysts and dilatations in cortical collecting duct; it increased cortical cell proliferation and inactive pGSK‐3β abundance; it lowered aquaporin‐2 (AQP2) protein abundance and induced polyuria with decreased ability to concentrate the urine; and it increased COX‐2 protein level in thick ascending limb. Concomitant treatment with lithium and a specific COX‐2 inhibitor, parecoxib (5 mg/kg per day, P10–P34), did not prevent lithium‐induced microcysts and polyuria, but improved urine concentrating ability transiently after a 1‐desamino‐8‐D‐arginine vasopressin challenge. COX‐2 inhibition did not reduce cortical lithium‐induced cell proliferation and phosphorylation of glycogen synthase kinase‐3β (GSK‐3β). COX‐1 protein abundance increased in rat kidney cortex in response to lithium. COX‐1 immunoreactivity was found in microcyst epithelium in rat kidney. A human nephrectomy specimen from a patient treated for 28 years with lithium displayed multiple, COX‐1‐immunopositive, microcysts. In chronic lithium‐treated adolescent rats, COX‐2 is not colocalized with microcystic epithelium, mitotic activity, and inactive pGSK‐3β in collecting duct; a blocker of COX‐2 does not prevent cell proliferation, cyst formation, or GSK‐3β inactivation. It is concluded that COX‐2 activity is not the primary cause for microcysts and polyuria in a NaCl‐substituted rat model of lithium nephropathy. COX‐1 is a relevant candidate to affect the injured epithelium.Keywords
Funding Information
- The Novo Nordisk Foundation
- The Lundbeck Foundation
- The Hørslev Foundation
- Bjørnow Foundation
- AJ Andersen Foundation
- Jacob and Olga Madsen Foundation
- Danish Medical Association Research Foundation
This publication has 39 references indexed in Scilit:
- Tissue injury after lithium treatment in human and rat postnatal kidney involves glycogen synthase kinase-3β-positive epitheliumAmerican Journal of Physiology-Renal Physiology, 2012
- Lithium reduces aquaporin-2 transcription independent of prostaglandinsAmerican Journal of Physiology-Cell Physiology, 2012
- αENaC-Mediated Lithium Absorption Promotes Nephrogenic Diabetes InsipidusJournal of the American Society of Nephrology, 2011
- Mice lacking mPGES-1 are resistant to lithium-induced polyuriaAmerican Journal of Physiology-Renal Physiology, 2009
- Postnatal adrenalectomy impairs urinary concentrating ability by increased COX-2 and leads to renal medullary injuryAmerican Journal of Physiology-Renal Physiology, 2007
- COX-2 activity transiently contributes to increased water and NaCl excretion in the polyuric phase after release of ureteral obstructionAmerican Journal of Physiology-Renal Physiology, 2007
- Valdecoxib: Assessment of Cyclooxygenase-2 Potency and SelectivityThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cellsCurrent Biology, 1996
- Growth hormone mRNA in mammary gland tumors of dogs and cats.Journal of Clinical Investigation, 1995
- Functional and Structural Changes in the Rat Kidney by Long-Term Lithium TreatmentKidney and Blood Pressure Research, 1982